China's first domestically developed trifocal toric intraocular lens addresses cataract, presbyopia, and astigmatism simultaneously — representing a breakthrough in refractive cataract surgery.
• China's first trifocal toric IOL — approved by NMPA
• Simultaneous correction — cataract, presbyopia (near, intermediate, distance vision), and astigmatism
• Domestic innovation — breaks the import monopoly in premium IOL segment
• Cost advantage — significantly more affordable than imported premium IOLs
I. Introduction: The Evolution of Cataract Surgery
Cataract surgery has evolved from a simple vision-restoring procedure to a refractive procedure — patients today expect not just improved vision, but freedom from glasses for distance, intermediate, and near vision.
Premium intraocular lenses (IOLs) have transformed cataract surgery. Multifocal and toric IOLs provide patients with a range of vision and correct astigmatism, significantly improving quality of life. However, these lenses have historically been dominated by Western manufacturers, with high prices that limit access in many markets.
In 2026, China approved its first domestically developed trifocal toric IOL — a lens that simultaneously addresses cataract, presbyopia, and astigmatism, offering patients a comprehensive visual solution.
I. Technology Overview
Optical Design
The trifocal toric IOL features a diffractive optical design that creates three focal points:
- Distance vision — for driving and daily activities
- Intermediate vision — for computer work and reading instruments
- Near vision — for reading and close-up work
The toric component corrects astigmatism by compensating for the patient's corneal curvature, eliminating the need for separate astigmatic correction.
Material
The lens is made from hydrophobic acrylic material, which:
- Minimizes posterior capsular opacification (PCO)
- Reduces glare and halos associated with some multifocal lenses
- Provides excellent biocompatibility
- Enables small-incision implantation
II. Clinical Evidence
Clinical studies of China's trifocal toric IOL have demonstrated:
- Excellent uncorrected visual acuity at distance, intermediate, and near in over 85% of patients
- Significant astigmatic correction — reducing postoperative cylinder to under 0.5 diopters
- High patient satisfaction — over 90% of patients reporting independence from glasses for daily activities
- Low rates of photic phenomena — minimal glare and halos compared to historical controls
III. Regulatory Status
The trifocal toric IOL has received NMPA approval and is now commercially available in China. This marks the first domestically developed premium IOL capable of simultaneous correction of cataract, presbyopia, and astigmatism.
IV. Clinical Adoption
Multiple Chinese ophthalmology centers have adopted the trifocal toric IOL, with early clinical experience demonstrating:
- Reliable rotational stability — critical for toric IOL performance
- Excellent visual outcomes across all distances
- High patient satisfaction with visual quality
- Cost savings compared to imported premium IOLs
V. What This Means for International Patients
For international patients considering cataract surgery in China:
- Access to premium, domestically developed IOLs — with outcomes comparable to imported premium lenses
- Cost advantage — cataract surgery with premium IOLs in China is significantly more affordable than in the U.S. or Europe
- Comprehensive visual correction — addressing cataract, presbyopia, and astigmatism in a single procedure
- Expert surgical care — Chinese ophthalmologists are among the most experienced in the world
Conclusion
China's trifocal toric intraocular lens represents a major advancement in cataract surgery — providing patients with comprehensive visual correction at an affordable price. As the first domestically developed premium IOL capable of simultaneously addressing cataract, presbyopia, and astigmatism, it marks a significant step forward for Chinese ophthalmic technology.